Objective: A cerebrospinal fluid leak is one of the most serious complications in otolaryngology. It may occur as a result of injury to the skull base, typically traumatic or iatrogenic. While the presence of a leak is often discerned in the emergent setting, distinguishing normal secretions from those containing cerebrospinal fluid can be difficult during postoperative visits in the clinic. As most current laboratory‐based assays are labor intensive and require several days to result, we aim to develop a more user‐friendly and rapid point‐of‐care cerebrospinal fluid detection device.Study Design: Our laboratory developed a barcode‐style lateral‐flow immunoassay utilizing antibodies for beta‐trace protein, a protein abundant in and specific for cerebrospinal fluid, with a concentration of 1.3 mg/L delineating a positive result.Setting: Tertiary medical center.Subjects and Methods: Tests with known concentrations of resuspended beta‐trace protein and the contents of discarded lumbar drains (presumed to contain cerebrospinal fluid) were performed to validate our novel device.Results: Our results demonstrate the ability of our device to semiquantitatively identify concentrations of beta‐trace protein from 0.3‐90 mg/L, which is within the required range to diagnose a leak, thus making beta‐trace protein an excellent target for rapid clinical detection.Conclusion: Herein we detail the creation and initial validation of the first point‐of‐care cerebrospinal fluid detection device. This device is a feasible method to more efficiently and cost‐effectively identify cerebrospinal fluid leaks, minimize costs, and improve patient outcomes.
Objective: To evaluate the clinicopathologic characteristics of head and neck solitary fibrous tumors and features that may predict tumor recurrence.Study Design: Retrospective review.Setting: University of California–Los Angeles Medical Center.Methods: A single‐center retrospective study was conducted on pathologically confirmed cases of head and neck solitary fibrous tumors between 1996 and 2021. Patient demographics, clinical course, and histopathologic features were evaluated. Recurrence‐free survival was estimated via Kaplan‐Meier analysis.Results: A total of 52 patients were reviewed. The average patient age was 54.7 years (range, 15‐89). The most common subsite was the orbit (53.8%, n = 28), but other involved areas included the nasopharynx, paranasal sinuses, and scalp. The median tumor size was 2.95 cm (range, 1.3‐11.2). Strong STAT6 (100%) and CD34 (97.9%) expression was observed on immunohistochemistry. Almost all patients were initially managed with wide local excision; 82% of patients (n = 14) had positive margins on pathologic review; and 15% (n = 4) had recurrence at a median 28.5 months (range, 10‐113). White patient race was the only significant predictor of tumor recurrence. Patient age (≥55 years), tumor size (≥4), high mitotic rate, and disease subsite were not associated with recurrence.Conclusion: Head and neck solitary fibrous tumors demonstrate a significantly larger local recurrence rate as compared with their rate of metastasis. They can recur many years following initial therapy, warranting long‐term surveillance and follow‐up to assess for tumor recurrence.
4 March 2019 in Clinical Practice and Cases in Emergency Medicine
Pneumolabyrinth, defined as air within the labyrinth on high-resolution computed tomography, suggests that a perilymphatic fistula (PLF) is present. PLF describes an abnormal communication between the middle and inner ear, and can result in deafness, vertigo, and imbalance. In the setting of a penetrating injury to the temporal bone or inner ear, pneumolabyrinth should trigger prompt otolaryngology consultation and urgent surgical exploration. We describe a case in which a 49-year-old male presented with a traumatic PLF secondary to penetrating ear injury. Imaging demonstrated extensive pneumolabyrinth. Despite delay in diagnosis, expeditious surgical intervention resulted in successful preservation of inner ear function.
Objectives: Cisplatin is known to cause inner ear dysfunction. There is growing evidence that cisplatin‐induced demyelination of spiral or Scarpa's ganglion neurons may play an additional role in drug‐induced ototoxicity alongside afferent neuron injury. As Schwann cells produce myelin, there may be an opportunity to reduce ototoxic inner ear damage by promoting Schwann cell viability. This work describes a cellular model of cisplatin‐induced Schwann cell injury and investigates the ability of the antioxidant N‐acetylcysteine to promote Schwann cell viability. A local delivery system of drug‐eluting microparticles was then fabricated, characterized, and investigated for bioactivity.Methods: RSC96 rat Schwann cells were dosed with varying concentrations of cisplatin to obtain a dose curve and identify the lethal concentration of 50% of the cells (LC50). In subsequent experiments, RSC96 cells were co‐treated with cisplatin and both resuspended or eluted N‐acetylcysteine. Cell viability was assessed with the CCK8 assay.Results: The LC50 dose of cisplatin was determined to be 3.76 μM (p = 2.2 x 10−16). When co‐dosed with cisplatin and a therapeutic concentration of resuspended or eluted N‐acetylcysteine, Schwann cells had an increased viability compared to cells dosed with cisplatin alone.Conclusion: RSC96 Schwann cell injury following cisplatin insult is characterized in this in vitro model. Cisplatin caused injury at physiologic concentrations and N‐acetylcysteine improved cell viability and mitigated this injury. N‐acetylcysteine was packaged into microparticles and eluted N‐acetylcysteine retained its ability to increase cell viability, thus demonstrating promise as a therapeutic to offset cisplatin‐induced ototoxicity.Level of Evidence: N/A Laryngoscope, 2023.
11 June 2024 in Otolaryngology–Head and Neck Surgery